Moreover, genetic variability in transketolase may result in susceptibility to diabetic polyneuropathy in newly diagnosed type 1 (T1D) and T2D patients. 
| INTRODUCTION
Diabetic patients endure substantial morbidity and premature mortality as a result of chronic diabetic complications, including nephropathy, retinopathy, and neuropathy. Several pathogenic factors downstream of high blood glucose cause chronic diabetic complications. 1 Most diabetics (60-70%) suffer neuropathy with many symptoms relying on the impaired nerves and the tissues regulated by these nerves. 2 Diabetic neuropathy leads to nontraumatic limb amputations. The diabetic duration, homeostasis model assessment for insulin resistance, haemoglobin A 1c , and increased glycaemic variability assessed by the mean amplitude of glycaemic excursions are all independent contributors to diabetic peripheral neuropathy in type 2 diabetic (T2D) patients. 3 The pathological mechanisms of diabetic neuropathy are nearly the same as diabetic retinopathy and nephropathy, such as oxidative stress, increased advanced glycation end products and their receptors, activation of the polyol pathway, inducible nitric oxide synthase, and activation of mitogen-activated protein kinases and protein kinase C. Moreover, increased cytokines (eg, nerve growth factor, tumour necrosis factor [TNF] α, and interleukin 6), hypoxia, and ischaemia deficiency are crucial etiologic roles for diabetic neuropathy. 4 Consistent with these findings, dysfunctional metabolic pathways in diabetes result in functional disorder, damage, and cell death, which are inherent to the peripheral nervous system (eg, Schwann cells, dorsal root ganglia neurons, and vasa nervorum).
Moreover, genetic variability in transketolase may result in susceptibility to diabetic polyneuropathy in newly diagnosed type 1 (T1D) and T2D patients. 5 Although various types of cells show the same molecular pathogenesis for hyperglycaemic damage in vitro, in vivo tissues have different influences on homeostatic and functional cellular responses to stressors. 6 Diabetes is associated with a substantially decreased number of blood bone marrow (BM) stem cells, and the depletion of stem cells contributes to diabetic neuropathy development. 7 Moreover, many clinical studies show that BM stem cells exhibit impaired function in diabetes. 8 Several studies in rats, mice, and humans indicate that diabetes contributes to numerous BM micro-environmental deficiencies (eg, neuropathy and microangiopathy) and damaged mobilization of stem cells (mobilopathy). [9] [10] [11] [12] The finding that diabetes influences BM stem cells involved in maintaining nerve homeostasis has been suggested as a bridging mechanism between BM stem cells and neuropathy in both local and distant tissues. To demonstrate the characteristics and mechanisms of BM pathology and BM stem cell function in diabetic neuropathy, we aimed to review the current findings on the pathology of diabetic BM, the exacerbation of diabetic neuropathy on the BM, and BM stem cell transplantation ameliorating diabetic neuropathy and its related mechanisms. A literature search was conducted using the databases MEDLINE, PubMed, and EMBASE. The search keywords contained "diabetes," "neuropathy,"
"inflammation," and "BM." No time or language limit was applied.
We also reviewed the references of selected papers to identify related articles.
| DIABETIC NEUROPATHY IN THE BM

| Pathology of diabetic BM
The BM is wrapped in the bone, which causes a sharp increase in pressure on the marrow. Thus, marrow oedema and the consequential passage of solutes from the blood, and hyperosmolarity may cause cell impairment and inhibition of haematopoiesis. 13 Arterial vessels enter the BM via the foramina nutricia and subsequently separate into capillaries, arterioles, and sinusoids, which permeate both central and endosteal marrow. The sinusoids are composed of a fenestrated endothelium and covered moderate pericyte. 14 The sinusoids function as a permeable barrier for haematopoietic stem cells (HSCs) to pass into the blood. This delicate structure is damaged by aging and diseases, which cause barrier impairment and niche destabilization. 15 It is important to note that the marrow is wrapped in a rigid container, which causes the marrow to be particularly sensitive to topical alterations in osmotic pressure as a result of plasma exudation. Impairment of endosteal or vascular cells leads to HSC exhaustion and BM failure. 16 The role of the BM in diabetes has been ignored for a long time;
however, the BM of diabetes shows a decreased small vessel density and relocation of HSCs according to a seriously decreased perfusion gradient across the marrow. 17 9 BM sympathectomy leads to impaired mobilization of stem cells triggered by granulocyte colony-stimulating factor (G-CSF) or hindlimb ischaemia in T1D and T2D mice. 9 One recent study shows that G-CSF exhibits a therapeutic effect on diabetic neuropathy in rats, at least partially due to the actions of BM cells. 25 Because of the regulative effect of the sympathetic nervous system on HSC trafficking, diabetic neuropathy is a critical incentive factor for BM dysfunction.
| BM stem cell niche
Diabetes ruins BM function, resulting in a stem cell niche-dependent fault in HSC mobilization. BM cells are both a victim and an accomplice in diabetes and diabetic complications. 26 The BM is the major reservoir for HSCs in adulthood, with a specific micro-environment (niche) to support and modulate HSCs. Transplanted primitive HSCs exist closer to the endosteum than more mature progenitors. 27 HSCs in the endosteum exhibit a higher self-renewal ability than those in the central marrow cavity. 28 Furthermore, aged HSCs exist far away from the endosteum than young HSCs, 29 which suggests that HSC location is affected by aging. The cell composition in the formation of the HSC niche in the BM includes osteoblast, endothelial, and perivascular cells. 30 Diabetes decreases the stem cell supportive ability of BM stroma. 31 As functional niche cells that line endosteal surfaces, osteolineage cells secrete substantial proteins that indirectly affect HSCs, including G-CSF, and contain surface molecules that hold HSCs in the niche. An increasing osteoblast number expands the HSC pool, 32 whereas the deletion of osteoblasts contributes to BM HSC depletion. 10 Among other cells in the endosteum, macrophages are regarded as regulators of HSC mobilization. G-CSFs, the mobilizing agent, decrease osteoblast number and suppress their activity, as well as downregulate the expression of C-X-C motif chemokine 12 (CXCL12), namely, stromal cell-derived factor 1α (SDF-1α), thus enabling the secretion of HSCs into the circulation. 33 The G-CSF receptor is expressed in macrophages, and G-CSF suppresses osteocalcin and CXCL12α production, which results in osteoblast reduction and HSC mobilization. 34 Many macrophages located in the endosteal area indirectly modulate HSC retention by modulating the osteoblast number. 35 impairs MSC existence and function and also lead to BM niche impairment that fundamentally causes haematopoietic malignancy. G-CSF administration in mice improves HSC traffic and the generation of granulocytes, as well as drives sympathetic neurons to secrete norepinephrine in the BM micro-environment ( Figure 1 , Table 1 ). Activation of β 3 -adrenergic receptors downregulates CXCL12 in BM stromal cells; nevertheless, β 2 -adrenergic receptor stimulation upregulates clock gene expression. Both deficiencies in β 2 -and β 3 -adrenergic receptors impair enforced mobilization.
Katayama et al 48 
2006
Norepinephrine signalling regulates G-CSF-caused osteoblast depression, decreased expression of CXCL12 in the bone, and HSC traffic. Treatment with a β 2 -adrenergic agonist promotes mobilization in both control and norepinephrine-deficient mice.
Dang et al 52 
2015
In type 2 diabetic patients and mice, nociceptive fibres are decreased. Under ischaemia or following G-CSF stimulation, patients with neuropathy have a significant reduction in the mobilization of HSCs that express the main substance P receptor (neurokinin 1 receptor). After limb ischaemia, diabetic mice show an altered gradient concentration of substance P among the BM, peripheral blood, and limb muscles, with a suppressed recruitment of HSC expression neurokinin 1 receptor to the ischaemic site.
Albiero et al 9 
2014
These results imply that autonomic neuropathy in BM damages stem cell traffic in diabetes with maladjustment of the lifespan modulators p66Shc and sirtuin 1.
Yamazaki et al 53 
2011
Nonmyelinating Schwann cells in BM are in charge of HSC activation. These Schwann cells wrap around autonomic nerves, express HSC niche factor genes, and contact a large amount of HSCs. Autonomic nerve denervation decreases the number of these active transforming growth factor β-producing cells and causes the rapid loss of HSCs from BM.
Abbreviations: BM, bone marrow; CXCL12, C-X-C motif chemokine 12; G-CSF, granulocyte colony-stimulating factor; HSC, haematopoietic stem cell; MSC, mesenchymal stem cell.
cells through the β 3 -adrenergic receptor, thereby causing a decreased nuclear level of specificity protein 1 transcription factor and the rapid downregulation of CXCL12. 44 These results imply that a circadian, Both deficiencies in β 2 -and β 3 -adrenergic receptors impair enforced mobilization. 51 Thus, β 2 -and β 3 -adrenergic receptors play important roles in stromal cells and cooperate to mobilize progenitors. 
| BM EPCs improve diabetic neuropathy by dual angiogenic and neurotrophic effects
Likewise, the motor and sensory nerve conduction velocities, capillary density, and blood flow are suppressed in the sciatic nerves of diabetic 
2015
BM macrophages impede stem cell mobilization by oncostatin M secretion, and oncostatin M antagonism is a target to recover BM function in diabetes.
Winkler et al 35 
2010
BM macrophages are pivotal to maintain the endosteal HSC niche, and the loss of these macrophages results in the egress of HSCs into blood.
Chow et al 36 
2011
Reductions in BM mononuclear phagocytes lead to decreased BM CXCL12 levels, the selective downregulation of HSC retention genes in nestin + niche cells, and egress of HSCs/progenitors to the bloodstream. Specific depletion of CD169 + macrophage, which spares BM monocytes, is sufficient to induce HSC/progenitor egress.
Casanova-Acebes et al 67 
2013
Modulation of the niche depends on macrophages and activation of cholesterol-sensing nuclear receptors and is essential for the rhythmic egress of haematopoietic progenitors into the circulation.
Urabe et al 68 
2016
BM cell-specific TNF-α is indispensable for diabetic peripheral neuropathy development; its selective depletion in a small proinsulin-producing BM cell subpopulation prevents diabetic peripheral neuropathy.
Dominguez et al 69 2015
Combination therapies protect against streptozotocin diabetes-induced impairment of nerve conduction velocity. The treatments also suppress the contents of granulocyte colony-stimulating factor, interleukin 1β, and matrix metalloproteinase-2 in diabetic BM supernatant and downregulate the expressions of NADPH oxidase 2, inducible nitric oxide synthase, and NF-κB1 mRNA in BM progenitor cells. Transplantation of haematopoietic mononuclear cells is related to an amelioration in motor nerve conduction velocity consequent to arteriogenic effects in the sciatic nerve without angiogenesis, and VEGF may result in this effect.
Abbreviations: BM, bone marrow; EPC, endothelial precursor cell; MSC, mesenchymal stem cell; RAGE, receptor for advanced glycation end product.
mice; however, they are restored to normal levels after hindlimb injection of autologous BM EPCs from normal C57BL/6J mice. Injected angiogenesis, and myelination increases in MSC-injected nerves. 62 These results suggest that BM MSC transplantation ameliorates diabetic neuropathy via peripheral nerve neurotrophic effects, angiogenesis, and neural regeneration (myelination).
| BM MSCs increase neurotrophic factor expression to promote diabetic peripheral nerve repair
Another study shows that autologous transplantation of normal BM MSCs ameliorates diabetic neuropathy in rats. 70 from BM impairment caused by diabetes. 18 In the BM of long-term T1D mice, the cytokine expressions of insulin-like growth factor 1, insulin-like growth factor binding protein 5, VEGF, and osteoprotegerin are upregulated. 39 Together with downregulated expression of the Bmil gene that inhibits HSC senescence, these alterations might be in charge of the compromised repopulation ability of the diabetic BM stem cell niche. 39 One recent study shows that increased recruitment of macrophages from the BM to the dorsal root ganglion is related to severe dorsal root ganglion histopathology and intraepidermal nerve fibre density loss. Table 2 ).
| BM macrophage M2 improves postinjury sciatic nerve regeneration
Deletion of the receptor for advanced glycation end products (RAGEs) in diabetic mice leads to increased conduction velocities and myelin- Oncostatin M is confirmed as the soluble mediator in M1 conditioned medium, which stimulates the expression of CXCL12 through a MEK-p38-STAT3-dependent signalling pathway.
Oncostatin M neutralization inhibits CXCL12 induction and promotes G-CSF and ischaemia-induced mobilization, vascular recovery, and stem cell migration to ischaemic muscles in diabetic mice. In diabetic patients, the BM blood oncostatin M concentration is increased and related to the BM-to-peripheral blood stem cell ratio. 66 These results indicate that BM macrophages impede stem cell mobilization by oncostatin M secretion, and oncostatin M antagonism is a target to recover BM function in diabetes.
| BM macrophages promote HSC retention by increasing CXCL12 expression
It is reported that circadian oscillation in the elimination of geriatric neutrophils by macrophages in the BM leads to these circadian alterations in HSC circulation and CXCL12 expression. 67 Accordingly, macrophages regulate the CXCL12 expression by nestin-GFP + cells
and HSC retention in the BM. 35, 36 Macrophages are one of the pivotal niche-regulating cells in light of their effect on nestin-expressing niche cells to ameliorate HSC retention by stimulating CXCL12 release. 34, 36 Macrophages own a parallel and antagonistic role compared with sympathetic nerves. 36 G-CSF administration in mice (which improves the mobilization of HSCs and generation of granulocytes) exhausts osteoblastic cells and macrophages. 34, 35 The G-CSF receptor is not expressed on osteoblastic cells, which indicates that osteoblast suppression occurs indirectly, likely through signalling in BM macrophages. 34, 35 Likewise, BM monocyte/macrophage changes may act as an inflammatory drive of HSC retention versus traffic in diabetes. T2D
impacts the BM-to-peripheral circulation distribution of M1 (proinflammatory) and M2 (anti-inflammatory) monocyte macrophages.
T2D also affects the M1/M2 mobilizing efficiency of G-CSF. 83 The pathway associated hyperglycaemia with an interrupted myelogenesis is confirmed and participates in the upregulated expression of the RAGE ligands by neutrophils. 84 Alterations in BM myeloid cells may thus cause diabetic stem cell mobilopathy. 36 In an inflammatory environment, stem and progenitor cell migration is controlled by prostaglandins and may be regulated by suppressing the synthesis of prostaglandin with nonsteroidal anti-inflammatory drugs. 85 tion. However, BM MSC transplantation has no effect on hyperalgesia unless it occurs during the first 4 days after injury ( Figure 1 , Table 2 ). 
| T cells and its Wnt10b are required to expand HSCs
